Ligelizumab treatment for severe asthma: learnings from the clinical development programme-Reference-Cited by-同舟云学术

Ligelizumab treatment for severe asthma: learnings from the clinical development programme

Published:2021-01 Issue:3 Volume:10 Page:
ISSN:2050-0068
Container-title:Clinical & Translational Immunology
language:en
Short-container-title:Clin Transl Immunol

Author:

Trischler Jordis¹,Bottoli Ivan²,Janocha Reinhold²,Heusser Christoph²,Jaumont Xavier²,Lowe Phil²,Gautier Aurelie²,Pethe Abhijit²,Woessner Ralph²,Zerwes Hans‐Günter²,Zielen Stefan¹

Affiliation:

1. Department for Children and Adolescents Division of Allergology, Pulmonology and Cystic fibrosis University Hospital Frankfurt am Main Frankfurt am Main Germany

2. Novartis Pharma AG Basel Switzerland

Publisher

Wiley

Subject

General Nursing,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cti2.1255

Reference31 articles.

1. Omalizumab for asthma in adults and children;Normansell R;Cochrane Database Syst Rev,2014

2. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

3. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE

4. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

5. Omalizumab Protects against Allergen- Induced Bronchoconstriction in Allergic (Immunoglobulin E-Mediated) Asthma

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways;Immunological Reviews;2024-08-19

2. Cellular senescence-Related genes define the immune microenvironment and molecular characteristics in severe asthma patients;Gene;2024-08

3. Safety, Tolerability, Pharmacokinetics, and pharmacodynamics of YH35324, a novel Long-Acting High-Affinity IgETrap-Fc protein in subjects with Atopy: Results from the First-in-Human study;International Immunopharmacology;2024-03

4. Atopy in chronic urticaria: an important yet overlooked issue;Frontiers in Immunology;2024-02-06

5. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials;The Lancet;2024-01